QuantLogix ← PFE scorecard
📅 PFE Earnings Preview
Pfizer Inc.
Next report (est.)
September 18, 2026
Countdown
97 days
EPS growth YoY
-9.6%
Revenue growth YoY
+5.4%
Implied vs actual — last 8 reports
ReportOptions impliedActual moveMarket was
May 5, 2026 ±2.3% +0.6% over-priced
November 4, 2025 ±1.8% -1.5% over-priced
August 5, 2025 ±2.0% +5.2% under-priced
May 5, 2025 ±3.0% -1.4% over-priced
November 4, 2024 ±2.0% -1.2% over-priced
August 5, 2024 ±3.5% -2.3% over-priced
May 8, 2024 ±3.3% +1.8% over-priced
November 8, 2023 ±1.9% -1.4% over-priced
Across these reports, options implied an average ±2.5% move vs an actual average of 1.9% — the stock stayed inside the implied band 88% of the time.
Fundamentals into the print
QuarterEPS (dil.)RevenueNet income
Q1 FY2026 $0.47 $14.5B $2.7B
Q4 FY2025 $-0.29 $17.6B $-1.6B
Q3 FY2025 $0.62 $16.7B $3.5B
Q2 FY2025 $0.51 $14.7B $2.9B
Analyst posture
Buy / Strong Buy
15
Hold
18
Sell
3
Stable: +0 net change 30d
Live 5-factor engine read: Buy · 57/100 Full scorecard →
Get alerted before every PFE report — free Full live analysis
🤖 Pro runs a 10-agent AI debate on PFE before the print — 5 analysts, bull vs bear, a risk read, and a trader's verdict. See Pro →

Pfizer Inc. (PFE) reports in 97 days, with the next report estimated for September 18, 2026. Across the last 8 reports, options priced an average ±2.5% earnings move while the stock actually moved 1.9% on average — the market has systematically over-priced PFE's earnings risk. Fundamentals into the print: EPS down 9.6% year-over-year, revenue up 5.4%. QuantLogix's live 5-factor engine currently reads PFE as a buy at 57/100.

Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →